Leading the Charge in Autoimmune Innovation

Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company’s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys’ position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies. Dr. Kress holds graduate and post-graduate degrees in biochemistry and molecular and cellular pharmacology from Ecole normale superieure, Paris, and an M.D. from Faculte Necker-Enfants Malades, Paris.

Mr. Mahatme joins Vor Bio with more than 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation. He most recently served as President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., a biomanufacturing company he co-founded in 2020. During his tenure, he raised over $2.5 billion in equity and non-dilutive capital.

Prior to Resilience, Mr. Mahatme served as Executive Vice President, Chief Financial Officer and Chief Business Officer of Sarepta Therapeutics, where he led capital formation efforts exceeding $3.5 billion and built the company’s pipeline through a series of strategic licenses, collaborations, and acquisitions. He also served as Senior Vice President, Corporate Development and Corporate Treasurer and Senior Vice President, Tax at Celgene Corporation. Mr. Mahatme currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals. He holds Master of Laws degrees from Cornell Law School and New York University School of Law and is a member of the New York Bar.

Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of successful development and execution of clinical trials for telitacicept across four key indications, systemic lupus erythematosus (SLE), Sjögren’s syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA), culminating in regulatory approvals in China for the treatment of SLE, generalized MG and RA.

Dr. Zuraw has also previously held senior leadership roles at Janssen Research & Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology.

Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies.

He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy.

Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson.

Mr. Murray holds an MBA from Queen’s University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta.

Dr. Osovsky brings nearly two decades of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. She joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. In that role, she led the company’s corporate legal and compliance activities and oversaw information technology.

She previously held senior legal roles at Sarepta Therapeutics, supporting corporate transactions, securities matters, and governance through a period of rapid growth and transformation.

Dr. Osovsky holds an LL.B. from Tel Aviv University and both an LL.M. and an S.J.D. in Securities Regulation from Harvard Law School.